MOH (Syria)

The Ministry of Health of the Syrian Arab Republic is the national authority for the regulation of human medicines, biologicals, vaccines, medical devices, in vitro diagnostics, cosmetics, dietary supplements, and pharmacy practice. The Ministry is headquartered in Damascus and reports to the Council of Ministers through the Minister of Health. Within the Ministry, the Directorate of Pharmaceutical Affairs (DPA) administers drug registration, pricing, pharmaceutical inspections, and pharmacy practice coordination. Scientific testing and official control are supported by the Syrian Drug Quality Control and Research Laboratory, while the Syrian Pharmacovigilance Centre coordinates collection and evaluation of safety information. Dedicated directorates oversee medical devices and IVDs, cosmetics, and dietary supplements.

The core legal instruments include Law 5 of 1990 on pharmacy practice and pharmaceutical establishments, Decree 14 of 1971 on pharmaceutical manufacturing, and Law 2 of 1993 on narcotics and psychotropics, which is substantively aligned with the UN drug control conventions of 1961, 1971, and 1988. Ministerial decisions, circulars, and DPA procedural notices operationalize these laws, define dossier formats and forms, set pricing methodologies, and specify inspection and vigilance expectations.

Syria historically maintained one of the larger domestic pharmaceutical manufacturing bases in the Arab region, with dozens of manufacturers serving most essential-medicine needs and exporting to regional markets. The post-2011 conflict and sanctions regime disrupted capacity, supply chains, and financial channels. In parallel, the Ministry opened structured cooperation with UN agencies and international NGOs to sustain access to quality-assured medicines, vaccines, and devices in humanitarian programs, while maintaining regulatory control over authorization, import, and post-market surveillance.

Regulatory operations are therefore a blend of statutory requirements, pragmatic risk-based controls, and interagency coordination. Sponsors should plan for Arabic-language submissions, source verification of GMP and quality data, official control testing for sensitive categories, and periodic updates during the product lifecycle. The Ministry participates in WHO Eastern Mediterranean networks and safety collaboration platforms to strengthen regulatory practice and convergence.

The Ministry’s remit covers the full lifecycle of human health products. This includes premarket authorization of medicines and biologicals, lot release for selected vaccines and biologics, classification and registration or listing of medical devices and IVDs, authorization of cosmetics and dietary supplements, and supervision of pharmacy practice. Controlled substances are tightly regulated across import, manufacture, distribution, and dispensing, in alignment with Law 2 of 1993. Parallel tracks exist for humanitarian operations when public health urgency or access constraints require accelerated pathways, but quality, safety, and documentation expectations remain material.

The framework applies to Syrian manufacturers, regional and global sponsors, importers, and authorized distributors. Entities seeking market access should anticipate document legalization requirements, Arabic labelling, and potential in-country testing on arrival. Depending on the product class, the Ministry may request additional stability, equivalence, or risk-management evidence, particularly for sterile injectables, cold-chain biologics, and devices with patient safety implications. Currency volatility and logistics complexity can affect pricing submissions, supply planning, and pharmacovigilance follow-up, so local regulatory support and contingency stock strategies are advisable.

In practice, scope determinations are made during pre-submission engagements with the Directorate of Pharmaceutical Affairs or the relevant device directorate. Sponsors commonly present classification rationales, comparators, and reference approvals to anchor the regulatory pathway. Humanitarian actors coordinate through established UN and NGO mechanisms while adhering to national import permits, lot testing, and distribution controls for high-risk categories.

• Human medicines and biologicals, including vaccines and blood-derivative therapeutics
• Medical devices and IVDs across risk classes, with classification confirmed by the device directorate
• Cosmetics and dietary supplements subject to authorization and labelling oversight
• Pharmacy establishments, wholesale distribution, and dispensing practices
• Controlled substances across import, manufacture, storage, and dispensing
• Humanitarian consignments requiring permits, quality evidence, and, where applicable, official control testing

Sponsors typically submit a dossier to the Directorate of Pharmaceutical Affairs structured to mirror internationally recognized formats. While Syria is not party to a single regional file, the core technical content follows the logic of the common technical document, with national administrative forms and Arabic-language components in Module 1. For generics, bioequivalence or biowaiver justifications are expected; for biologics and vaccines, quality, nonclinical, and clinical evidence supporting comparability, safety, and immunogenicity is emphasized. Humanitarian imports may be handled under accelerated procedures that rely on stringent regulatory authority decisions or WHO procurement references, while preserving verification and batch-control safeguards.

Chemistry, manufacturing, and controls should be mapped to current GMP, with clear evidence of process validation, analytical method validation, and impurity control. Syria’s review can focus on stability under regional climatic conditions, robustness of supply chains, and pharmacovigilance commitments tailored to the local context. For line extensions, variations, or renewals, administrative timelines and data requirements vary with change category and risk, and sponsors should confirm the latest procedural circulars before filing.

Impurity specifications and justifications should align with ICH principles; where generics reference a local or imported comparator, analytical equivalence and stability data underpins substitution safety. Sponsors often include a gap analysis to show how their controls meet Syrian requirements and any additional commitments applicable to supply through humanitarian channels.

Where applicable, align impurity justifications with ICH Q3A (impurities in drug substance), tailoring limits to the maximum daily dose and toxicological thresholds used internationally.

The Directorate of Pharmaceutical Affairs conducts pre- and post-approval GMP inspections of Syrian manufacturers and audits importers and warehouses for storage, distribution, and documentation controls. Evidence of current GMP compliance from exporting jurisdictions is expected for foreign manufacturers, supported by site master files, inspection reports where available, and detailed CMC documentation. For selected high-risk products, the Syrian Drug Quality Control and Research Laboratory performs independent batch testing as part of pre-release verification, with vaccine lots generally subject to official control testing upon import.

Sponsors should be prepared to demonstrate validated manufacturing processes, change control, deviation management, and data integrity governance. Syria’s inspectors commonly examine water systems, cleanroom classification and monitoring, aseptic process simulations, and sterility assurance for parenterals. For non-sterile products, emphasis often falls on microbial limits, cross-contamination prevention, and traceability of APIs and excipients through approved suppliers. Post-import, stability commitments under regional climatic conditions may be requested to support shelf-life and storage statements.

Batch release documentation should be complete and consistent with the approved dossier, including certificates of analysis, deviation summaries, and transportation records for cold-chain products. When humanitarian consignments are expedited, sponsors should expect intensified document scrutiny and, where risk warrants, confirmatory testing by the national laboratory before distribution.

The Ministry’s device and IVD oversight is organized through dedicated directorates that apply risk-based classification and require evidence of conformity with essential safety and performance principles. Sponsors generally submit classification rationales, device descriptions, risk management files, and labelling and instructions for use in Arabic. Depending on the class, quality system evidence such as ISO 13485 certification is expected, and clinical evaluation or performance evaluation may be required for higher-risk devices and IVDs.

Importers must hold appropriate licenses and designate local representatives. The Ministry may require proof of market clearance in reference jurisdictions for high-risk categories, with verification of manufacturing site controls and post-market surveillance plans. For IVDs used in public health programs, performance claims should be anchored in recognized standards and validated under conditions representative of Syrian laboratories. Humanitarian programs can leverage reliance on WHO or UN procurement references for priority diagnostics, subject to documentation and lot verification upon receipt.

Arabic labelling, clear IFUs, and traceability to batch or serial identifiers are central to device oversight. For sterile single-use products, sterility assurance levels, packaging validation, and shelf-life studies are examined closely. Software-enabled devices should include cybersecurity and update management statements consistent with the risk classification and clinical context of use.

The Syrian Pharmacovigilance Centre coordinates the collection, evaluation, and communication of safety information for medicines and vaccines. Marketing authorization holders and importers are expected to maintain complaint handling and adverse event reporting systems, designate responsible personnel, and submit expedited individual case safety reports in line with national timelines. Periodic aggregate reports may be requested for products with evolving safety profiles or for categories prioritized by public health programs.

Risk management plans should identify product-specific pharmacovigilance activities, risk minimization measures, and communication triggers. In humanitarian programs, field pharmacovigilance and quality surveillance often operate through joint protocols with UN agencies and NGOs to capture signals in challenging, high-mobility settings. For vaccines, the Ministry emphasizes monitoring of serious adverse events of special interest, cold-chain deviations, and lot-specific quality issues.

Post-market quality surveillance includes sampling and testing, inspection of distribution and pharmacy outlets, and investigation of falsified or substandard products when suspected. Recalls and market withdrawals are coordinated with the Ministry, with rapid communication to healthcare providers and the public when indicated. Sponsors should ensure that recall procedures, distribution records, and stakeholder contact trees are current and tested under realistic timelines. For background, see pharmacovigilance and post-market-surveillance.

Controlled substances are governed by Law 2 of 1993, which is substantively aligned with the UN drug control conventions. The Ministry authorizes procurement, import, manufacture, distribution, and dispensing through permits and quotas, with strict recordkeeping and security controls. Importers and healthcare institutions must maintain registers, reconcile stocks, and report discrepancies or theft promptly. Formulations containing psychotropics or narcotics require precise scheduling determinations and may trigger additional Ministry scrutiny at the dossier and import stages.

The post-2011 sanctions environment complicates financial flows, insurance, logistics, and spare parts support for health technologies. While humanitarian exemptions exist, sponsors should anticipate additional documentation to evidence end-use, consignee authorization, and quality assurance. Cold-chain management and transport route selection are scrutinized for vaccines and temperature-sensitive drugs. For medical gases, radiopharmaceuticals, and specialty injectables, safety and security measures during transit are reviewed closely.

Humanitarian programs administered through UN agencies or vetted NGOs often proceed under accelerated coordination, with reliance on approvals by stringent authorities or WHO procurement references for time-critical interventions. Nevertheless, import permits, customs declarations, and quality control remain mandatory. Sponsors should stage risk-based sampling, retain documentation for post-clearance audits, and ensure clear custody transfer to in-country health partners.

Arabic labelling is generally required for medicines, devices, IVDs, cosmetics, and dietary supplements. The Ministry reviews core safety and identification elements, ensuring clarity for patients and healthcare professionals. Dual-language presentations are frequently accepted where Arabic is primary and legible. Overstickers may be permitted for humanitarian consignments or time-sensitive imports, provided they are durable, accurate, and do not obscure critical information. Barcodes and serialization practices should align with the product’s distribution controls and local feasibility.

Pharmacy practice is supervised through licensing and inspection of community and hospital pharmacies. Dispensing controls for prescription-only medicines, narcotics, and psychotropics are enforced, including storage security and recordkeeping requirements. The Ministry monitors pricing and may adjust schedules to reflect currency fluctuations, input costs, and public health priorities. Sponsors should include transparent cost and supply documentation to facilitate price-setting deliberations by the Directorate of Pharmaceutical Affairs.

For medical devices, clear instructions for use, contraindications, warnings, and maintenance requirements in Arabic are essential. Patient-facing aids such as pictograms or stepwise guides reduce use errors in low-resource settings. Consistent label control across batches helps minimize recalls due to translation issues or artwork errors. Sponsors implementing centralized artwork management tools can reduce cycle time and proofing defects.

• Arabic product name and international nonproprietary name where applicable
• Strength, dosage form, pack size, batch number, and expiry date
• Storage conditions and special handling statements
• Manufacturer and country of origin, with local representative details
• Approved indications and directions for use for OTC categories
• Device or IVD classification symbol and sterility or single-use statements

Structured artwork control and versioning support compliance; see label-design for managing multilingual content and approvals.

Syria’s regulatory system operates within the WHO Eastern Mediterranean context and collaborates with UN agencies that procure and distribute essential medicines and diagnostics. While Syria is not part of a binding regional licensing system, the Ministry considers evidence from stringent authorities and WHO procurement references, especially for time-critical humanitarian needs. Sponsors with EMA, FDA, or other major-agency approvals can leverage those assessments to streamline Syrian reviews, subject to local data, Arabic labelling, and pricing.

Cross-border supply dynamics underscore the value of practical alignment. For example, Iraqi or Omani dossiers may share many components with Syrian filings, though national administrative forms and pricing differ. Sponsors frequently prepare a common technical core and maintain country-specific Module 1 adaptations. Distribution and vigilance systems should account for differing cold-chain, customs, and reporting expectations across borders, which can affect lead times and safety follow-up.

For reference frameworks in the region, see neighboring authorities such as Iraq MoH and Oman MoH, and related contexts such as Palestine MoH. Reliance on WHO procurement and who-prequalification outputs can expedite access for priority products when combined with Syrian administrative compliance, national labelling, and import controls.

Sponsors sometimes underestimate Arabic-language requirements and submit incomplete translations, which can delay approvals or prompt relabelling after arrival. Others rely on comparator products not available in Syria, complicating bioequivalence justifications for generics. Early alignment meetings with the Directorate of Pharmaceutical Affairs reduce these risks and help scope any additional data requests, particularly for sterile injectables and vaccines where local stability and cold-chain controls are scrutinized.

A second frequent pitfall is incomplete verification of quality system credentials for third-party manufacturers or critical suppliers. Missing audit reports, outdated cleaning validation, or weak data integrity controls draw inspection findings that cascade into lot holds. Sponsors should validate core CMC claims with current certificates and ensure coherent change-control narratives across dossier modules, batch records, and quality agreements.

On the device side, misclassification and thin clinical or performance evaluation files for higher-risk categories cause avoidable questions. Clear statements of intended purpose, risk-benefit rationales, and harmonized essential-principles checklists help avoid iterative queries. Post-market planning is sometimes reactive; building signal detection, complaint trending, and field corrective action procedures into the initial submission evidences lifecycle stewardship in Syria’s operating context.

Finally, humanitarian shipments occasionally proceed without synchronized permits, consignee credentials, and bank documentation to operationalize sanctions exemptions. Pre-validating documentation packages and shipment routings reduces customs dwell times and protects cold-chain integrity during clearance peaks.

Operating in Syria requires disciplined dossier management, robust GMP evidence, controlled Arabic artwork, and responsive pharmacovigilance and recall procedures. V5 Ultimate provides a unified quality and regulatory backbone that standardizes submissions and lifecycle controls while accommodating country-specific requirements. Sponsors can map their technical core to Syrian administrative forms and Arabic labelling, manage supplier assurance for complex globalized supply chains, and maintain inspection-ready data integrity across facilities and partners.

V5’s document and change control enforces versioned approvals for CMC files, instructions for use, and packaging components. Structured workflows guide stability plans, deviation closures, and temperature-excursion assessments for cold-chain goods. Integrated batch genealogy and distribution traceability provide rapid retrieval for market withdrawals and humanitarian replenishments. Teams can capture vigilance data, triage complaints, and maintain auditable communications with in-country representatives under compressed timelines.

When programs span multiple jurisdictions, V5 helps maintain a harmonized technical core with localized Module 1 content and pricing attachments, reducing cycle time and error risk. Sponsors can demonstrate alignment to WHO GMP principles, ISO 13485 expectations for devices, and Syrian administrative procedures, all within an inspection-ready platform that withstands document scrutiny by authorities and third-party auditors.